Analysis

Relationships with the drug industry: Build trust based on good science

BMJ 2009; 338 doi: 10.1136/bmj.b234 (Published 3 February 2009)
Cite this as: BMJ 2009;338:b234

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Scott Gottlieb, health policy analyst
  1. 1American Enterprise Unit, 1150 17th Street, NW, Washington, DC 20036, USA
  1. Scott.Gottlieb{at}mssm.edu

    The relationship between the drug industry, academia, healthcare professionals, and patients has reached an all time low and few doubt that it is in the interests of all parties to improve it. A recent report from the Royal College of Physicians attempts to define a path towards achieving a more productive relationship. Here we set out five contrasting views on what the ideal relationship between industry and prescribers and patients should be and what steps need to be taken to achieve it (doi:10.1136/bmj.b222, doi:10.1136/bmj.b211, doi:10.1136/bmj.b252, doi:10.1136/bmj.b232)

    Medical treatments are becoming increasingly more individual, with respect to both disease and patient. They are also becoming more complex, and precise diagnoses and close monitoring are needed to optimise …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular